Why do patients stop GLP-1 drugs
Through strategic collaborations and an expanding suite of healthcare solutions, the company keeps feeding its growth moves
[8] [9] GLP-1 medications work through several complementary mechanisms: Enhancing insulin secretion from pancreatic beta cells in response to elevated blood glucose Suppressing glucagon release , which reduces glucose production by the liver Slowing gastric emptying , helping you feel fuller for longer Acting on appetite centres in the brain to reduce hunger and food intake In the UK, commonly prescribed GLP-1 receptor agonists include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), lixisenatide (Lyxumia) and exenatide (Byetta, Bydureon)
The FDA warns that these products are of unknown quality and may be harmful
Semaglutide medications work by activating the GLP-1 receptor alone, while tirzepatide medications activate both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, creating what is commonly described as a dual incretin mechanism
Here are the main mechanisms: They boost insulin secretion after meals (but in a glucosedependent way, meaning they act more when blood sugar is higher)
